Skip Navigation

A Phase 1 First-in-Human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 administered intratumorally as monotherapy and in combination with cemiplimab in patients with advanced solid tumors.

Brief Summary


Study Type:

I Identifier:

Study #:

Start Date:
Jan 01, 0001

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT03871348

View Complete Trial Details & Eligibility at